

## 2024 - EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING

DISTRIBUITO DA:

**AB ANALITICA Srl**  
Via Svizzera, 16 – 35127 PADOVA  
Tel. +39 049 761698 – Fax +39 049 8709510  
e-mail: [customersupport@abanalitica.it](mailto:customersupport@abanalitica.it)  
website: [www.abanalitica.com](http://www.abanalitica.com)

Version number CAT2024/01

# **EQA FOR MOLECULAR INFECTIOUS DISEASE TESTING**

**QCMD (Quality Control for Molecular Diagnostics) is an independent External Quality Assessment (EQA) / Proficiency Testing (PT) scheme specialising in molecular testing of a wide range of infectious diseases.**

- 1** INTRODUCTION TO QCMD EQA SCHEMES
- 3** BENEFITS
- 4** HOW IT WORKS
- 5** EQA GROUPS (INDEX)
- 15** VIRAL EQA SCHEMES
- 43** BACTERIAL EQA SCHEMES
- 54** FUNGAL EQA SCHEMES
- 56** PARASITIC EQA SCHEMES
- 58** MULTI-PATHOGEN/SYNDROMIC EQA SCHEMES
- 65** EQA PILOT STUDIES
- 73** APPENDIX

# AN INTRODUCTION TO THE QCMD EQA SCHEMES

The aim of QCMD's External Quality Assessment (EQA) programmes or schemes is to help monitor and improve laboratory quality by assessing a laboratory's use of molecular testing for infectious diseases. The EQA schemes are both educational and regulatory in application and support continuous quality improvement, as well as assist laboratory accreditation / certification to ISO15189 or equivalent.

## Who can participate?

The EQA schemes are provided global either directly from QCMD or through one of many QCMD approved QA collaborators and distributors. To register or find out more go to [www.QCMD.org](http://www.QCMD.org)

## The EQA scheme format


All individual QCMD EQA schemes have their own design specifications which are agreed by the QCMD scientific experts / advisors for each scheme. The distribution frequencies (number of challenges per year) within an EQA scheme often vary in different countries due to regional regulatory requirements. As a result, QCMD offers a range of options from a single challenge per year to a 4 challenge EQA format per year depending on the EQA scheme.

Participants can select which EQA format is best for their laboratory and regulatory requirements.

Please note: if the EQA scheme format within the catalogue does not meet your specific requirements contact the QCMD office and we will see what we can do to help you.

For more details on the format of each of the EQA schemes see the individual EQA specifications within the catalogue or visit the QCMD website.

For example, the HIVRNA, HBV, and HCV BBV viral load EQA schemes are provided with the option of either 1, 2 or 4 challenges per year.



# AN INTRODUCTION TO THE QCMD EQA SCHEMES

## **EQA Distribution schedule**

The EQA schemes are distributed at set dates throughout the year. An outline of the distribution schedule is provided in appendix I and further details regarding the annual distribution schedule are provided on registration through the QCMD website ([www.qcmd.org](http://www.qcmd.org)). On receipt of the EQA panel the laboratory has a defined period of time to test the panel and return their results to QCMD through the secure web-based portal. An outline of the testing periods is also provided within appendix I.

## **QCMD EQA Reports & feedback**

After close of the EQA results return phase, Laboratories receive an individual report for the EQA challenge /scheme they have participated in. This provides an overview of their performance in relation to their method/technology type peer group and where appropriate the overall consensus from all participants within the EQA scheme.

On completion of the EQA scheme, a supplementary report may be provided (depending on the EQA scheme).

The supplementary report includes any relevant additional information regarding the recent EQA scheme, and where appropriate any Scientific Expert commentary / feedback on the overall EQA scheme results. Where required, National EQA providers or country specific EQA groups are also provided with an additional country specific EQA report.

## **Further information**

For further details register on line and visit your profile area, download the QCMD participant manual at [www.QCMD.org](http://www.QCMD.org)

# BENEFITS



## EXTENSIVE PROGRAMME OFFERING

Boasting the largest selection of molecular EQA programmes for infectious disease testing, you are sure to find what you're looking for.



## FREQUENCY

Choose between one, two and four challenges\* per year to suit your laboratory requirements. Reports are available within 2 weeks of the submission deadline (up to 4 weeks for the drug resistance / sequence based schemes), ensuring any corrective actions can be taken quickly.



## HIGH QUALITY MATERIAL

The availability of whole pathogen samples in clinically relevant matrices mimics the performance of patient samples and ensures samples can be used to effectively monitor the performance of the entire testing process.



## INTERNATIONAL ACCREDITATION

Where appropriate the EQA schemes are accredited to ISO 17043:2010 highlighting the superior quality and organisation of the QCMD scheme.



## ONLINE EQA MANAGEMENT SYSTEM

IT EQA Management System (ITEMS) provides an online tool to easily manage all EQA activities from programme registration to submission of results and provision of EQA reports.



## HIGH LEVEL OF PARTICIPATION

With over 10,000 participant registrations in more than 100 countries, peer groups are maximised, increasing statistical validity.



## COMPREHENSIVE REPORTS

Individual reports are provided with each EQA challenge. In line with the requirements of ISO17043, they provide the laboratories with their results and performance assessment in relation to their EQA assessment group (peer review group).


Supplementary reports which include scientific expert commentary may be provided at the end of the EQA cycle if appropriate.

\*programme dependent

# HOW IT WORKS

The QCMD portfolio is extensive covering over 300 target organisms across more than 90 EQA programmes and pilot studies.

The following diagram provides an overview of the schemes operation.



# EQA GROUPS

## BLOODBORNE VIRUS

The Bloodborne Virus (BBV) group of QCMD External Quality Assessment (EQA) schemes consists of pathogens that are detected from the blood. This includes human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) B19 virus (B19) and more recently hepatitis A virus (HAV), hepatitis E virus (HEV) and hepatitis D virus (HDV).

To compliment the detection and viral load determination schemes above a range of genotyping and drug resistance BBV EQA schemes are available.

For the drug resistance BBV EQA schemes different current resistance markers are included and emphasis is placed on the determination and interpretation of these resistance markers.

	Page Number		Page Number
B19 virus	15	Hepatitis C virus	25
HBV Dried Blood Spots	69	Hepatitis D virus	26
HBV Drug Resistance	21	Hepatitis E virus	26
HBV Genotyping	22	HIV-1 (DNA)	28
HCV Dried Blood Spots	69	HIV-1 (RNA)	28
HCV Drug Resistance	23	HIV-1 Dried Blood Spots	70
HCV Genotyping	24	HIV-1 Drug Resistance	29
Hepatitis A virus	24	HIV-1 Drug Resistance (Integrase)	29
Hepatitis B virus	25	HIV-2	30

### CENTRAL NERVOUS SYSTEM

Infections of the Central Nervous System (CNS) can occur indirectly via the blood following damage to the blood brain barrier or directly through intraneuronal routes. Encephalitis and meningitis are important CNS infections which can have viral, bacterial or parasitic origins.

Viral encephalitis can occur as a result of acute infection or as the consequence of latent infection. Common viral causes include herpes simplex virus (HSV), specific enteroviruses (EV), JC and BK virus, as well as Varicella- Zoster virus (VZV). Bacterial infections within the CNS such as meningitis can be a result of direct infection of the brain or may be due to underlying diseases which can lead to secondary CNS infection. Parasites such as *Toxoplasma gondii* can also cause CNS infections particularly in immunocompromised individuals.

In recent years significant advances have been made in understanding CNS pathogenesis with the development of molecular technologies for the diagnosis and monitoring of disease, the introduction of effective treatment therapies and, in some cases, the development of vaccines (e.g. Japanese encephalitis & rabies). The range of QCMD EQA schemes within this area focus on pathogens known to play a significant clinical role in CNS infection. The general aim of this group of EQA schemes is to assess the laboratories' ability in the detection and determination of the selected pathogen. Where appropriate pathogen load estimation is also evaluated.

	Page Number		Page Number
Arthropod-borne viruses	57	Herpes simplex virus 1 & 2	27
BK virus	16	Herpes simplex virus Drug Resistance	27
<i>Borrelia burgdorferi</i> spp. (Lyme Disease)	44	JC virus	35
Central nervous system CNS I (Viral Meningitis and Encephalitis)	58	Measles / Mumps	35
Central nervous system CNS II (Non-Viral Meningitis and Encephalitis)	58	Parechovirus	37
Chikungunya virus	16	<i>Toxoplasma gondii</i>	56
Dengue virus	19	Varicella-Zoster virus	40
Enterovirus	19	West Nile virus	41
Enterovirus typing	20	Zika virus	42



## CONGENITAL INFECTIONS

The term congenital infection is used to describe those infections transmitted from mother to child either during pregnancy (Transplacental infection) or immediately after childbirth. They can be caused by viruses, bacteria and on occasion parasites. The ability of a particular pathogen to cross the placenta and infect the foetus /embryo is dependent on many factors including the mother's immune status. Primary infections during pregnancy can result in spontaneous abortion or major developmental disorders if undetected and left untreated.

In recent years the diagnosis of congenital infections has been significantly improved by the ability to obtain clinical samples such as blood through chorionic villus sampling. In addition, the application of molecular technologies has helped significantly in the diagnosis, monitoring, and treatment rationale. CMV Dried Blood Spots is one of the EQAs provided in this disease group.

	Page Number		Page Number
Chagas	66	<i>Toxoplasma gondii</i>	56
Cytomegalovirus Dried Blood Spots	18		

## DRUG RESISTANCE

The ability of microorganisms to adapt and develop resistance to antimicrobials is natural and an evolutionary trait they have been employing for thousands of years. Hence there are many examples of drug resistant strains in viral, bacterial and parasitic diseases. However, it is well recognised that the over prescription of antimicrobials within clinical practice and their overuse in domestic products has helped to accelerate drug resistance, and led to the emergence of multidrug resistance.

QCMD has established a range of Drug Resistance EQA schemes covering a variety of pathogen types. The primary aims of these schemes are to assess the laboratory in their ability to detect and determine the presence of drug resistance at the molecular level. In addition some of the schemes also cover drug resistance interpretation.

	Page Number		Page Number
CMV Drug Resistance	17	HIV-1 Drug Resistance	29
Extended Spectrum $\beta$ -lactamase and Carbapenemase	47	HIV-1 Drug Resistance (Integrase)	29
HBV Drug Resistance	21	Methicillin Resistant <i>Staphylococcus aureus</i>	50
HCV Drug Resistance	23	<i>Mycobacterium tuberculosis</i> Drug Resistance	51
Herpes simplex virus Drug Resistance	27	Vancomycin Resistant Enterococci	53

## EXOTIC/EMERGING DISEASES

A complex relationship exists between pathogen genetics, host and the environment. As a result, predicting the future emergence of exotic diseases is difficult. However, globalisation coupled with rapid increases in human populations over the last 50 years has played an important role. Local environmental changes such as deforestation due to urbanisation bring humans into closer contact with potential new pathogen vectors. These factors disturb the subtle balance between pathogen, host and the environment and create the opportunity for the emergence of new disease pathogens or the re-emergence of existing pathogens. These diseases can be caused by newly identified pathogens, pathogen strains such as SARS or the mutation of existing strains such as Influenza virus. In addition, the spread of known pathogens (e.g. West Nile virus & dengue virus) into new geographical areas leading to new potential endemics account for a large number of exotic / emerging diseases. The EQAs within this group focus on those emerging diseases that are frequently being identified within progressive geographic regions.

	Page Number		Page Number
Arthropod-borne viruses	57	MERS coronavirus	36
Babesia	65	Poxviruses	72
Chagas	67	Respiratory I Plus	60
Chikungunya virus	16	SARS-CoV-2	39
Dengue virus	19	SARS-CoV-2 Antigen Testing	39
<i>Francisella tularensis</i>	68	West Nile virus	41
Malaria	71	Yellow fever virus	41

## GASTROINTESTINAL DISEASES

Gastroenteritis can be caused by a wide variety of bacteria, viruses and parasites. It is often associated with severe inflammation of the gastrointestinal tract involving both the stomach and small intestine. This results in acute diarrhoea and vomiting.

Diagnosis is primarily based on clinical symptoms, but laboratory diagnosis on the etiological cause is often needed in order to support patient care. In recent years molecular diagnostic techniques such as real-time PCR have also been introduced for the laboratory diagnosis of gastroenteritis, including the ability to simultaneously screen for a wide range of enteric pathogens using multiplex assays. As a result, molecular diagnostic techniques are increasingly being used in the routine laboratory setting for detection, determination and surveillance of a wide range of enteric pathogens.

The general aim of this group of EQA schemes is to allow laboratories to assess their ability in the use of molecular diagnostic tests for a range of viral, bacterial and parasitic enteric pathogens.

	Page Number		Page Number
Adenovirus	15	<i>Helicobacter pylori</i>	48
Bacterial Gastroenteritis	57	Norovirus	36
<i>Clostridium difficile</i>	46	Parasitic Gastroenteritis	59
Diarrheagenic <i>Escherichia coli</i>	47	Viral Gastroenteritis	64

### IMMUNOCOMPROMISED ASSOCIATED DISEASES

The treatment and management of patients with compromised immune systems has seen important developments in recent years with, for example, the introduction of novel multi-drug treatment regimes. As a result, the healthcare and management of immunocompromised patients has greatly improved. However, pathogen infection or viral reactivation remain significant contributors to morbidity and mortality in these patients.

A number of opportunistic parasitic, fungal and viral pathogens are of concern in the management of immunocompromised patients due to both acute infection and reactivation of latent virus in the immunocompromised host.

Advances in molecular diagnostics have allowed accurate pathogen assessment and quantitative monitoring, particularly of viral activity over time, which allows early and accurate pre-emptive intervention and management of antiviral drug therapy.

The range of QCMD EQA schemes within this area focus on pathogens known to play a significant clinical role in the management of immunocompromised patients. The general aim of this group of EQA schemes is to assess the ability of laboratories in the detection of the selected pathogen and where appropriate quantitative estimation is also evaluated.

	Page Number		Page Number
<i>Aspergillus</i> spp.	54	Epstein-Barr virus Whole Blood	21
Babesia	65	Human cytomegalovirus	30
BK virus	16	Human herpes virus 6	31
Candida spp.	54	JC virus	35
Chagas	66	<i>Pneumocystis jirovecii</i> pneumonia (PCP)	55
CMV Drug Resistance	17	Torque teno virus	40
Cytomegalovirus Whole Blood	18	<i>Toxoplasma gondii</i>	56
Epstein-Barr virus	20	Transplantation (viral)	65

### MULTIPLE PATHOGEN/SYNDROMIC

Multiplex based molecular diagnostic tests offer the ability for the detection of a wide range of pathogens within a single diagnostic test.

Syndromic approaches to test respiratory, gastroenteritis and meningitis infections allows clinicians to identify the cause of infection from a wide range of pathogens often in a near patient, point of impact setting where rapid diagnosis aids faster clinical decision making and patient treatment. These technologies are generally used as a screening approach where identification of pathogens allow improved patient management at initial point of contact.

QCMD have introduced multi-pathogen/syndromic schemes to address this growing need in the clinical setting. A range of schemes cover respiratory infections, transplant associated infections, central nervous system infections, sexually transmitted infections and gastroenteritis infections caused by a range of aetiologies.

	Page Number		Page Number
Arthropod-borne viruses	57	Respiratory I plus	60
Bacterial Gastroenteritis	57	Respiratory II	61
Central Nervous System I (Viral Meningitis and Encephalitis)	58	Respiratory III	61
Central Nervous System II (Non-Viral Meningitis and Encephalitis)	58	Sepsis	62
<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoea</i>	45	Sexually Transmitted Infections I	62
MALDI-TOF	59	Sexually Transmitted Infections II	63
Parasitic Gastroenteritis	59	Transplantation (viral)	65
Respiratory I	60	Viral Gastroenteritis	64

### RESPIRATORY DISEASES

Respiratory tract infections (RTIs) are common conditions, experienced by most adults and children each year. They can affect both the upper and lower respiratory tract and range from the common cold to viral and bacterial pneumonia. For the young, the elderly and the immune compromised, RTIs can be a significant health threat if not managed effectively.

RTIs can be caused by a large number of bacterial, viral and fungal pathogens which have nearly indistinguishable physiological symptoms. This can increase the chances of undiagnosed or misdiagnosed infections leading to patients either not receiving critical medications, or receiving unnecessary antibiotics. The advance of molecular diagnostic techniques has improved our ability to rapidly determine the causative agents of RTIs and has the potential to improve patient management, control of nosocomial transmission and promote targeted therapy.

The Respiratory EQA schemes cover 17 of the major viral, bacterial and fungal causes of RTIs, focusing on the pathogen load and allowing assessment of the laboratories ability to accurately identify the species of interest at clinically relevant levels.

	Page Number		Page Number
Adenovirus	15	<i>Mycobacterium tuberculosis</i>	50
Atypical mycobacterium	43	<i>Mycobacterium tuberculosis</i> Drug Resistance	51
<i>Bordetella pertussis</i>	44	<i>Mycoplasma pneumoniae</i>	52
<i>Chlamydia psittaci</i>	45	Parainfluenza virus	37
<i>Chlamydophila pneumoniae</i>	46	<i>Pneumocystis jirovecii</i> pneumonia (PCP)	55
Coronavirus	17	Respiratory I	60
Group A Streptococcus	68	Respiratory I plus	60
Human metapneumovirus	31	Respiratory II	61
Influenza A & B virus	34	Respiratory III	61
Influenza Typing	34	Respiratory syncytial virus	38
<i>Legionella</i> spp.	49	Rhinovirus	38
Measles / Mumps	35	SARS-CoV-2	39
MERS coronavirus	36	SARS-CoV-2 Antigen Testing	39

### SEXUALLY TRANSMITTED INFECTIONS

Sexually transmitted infections (STIs) remain a major public health concern throughout the world with some infections reaching epidemic proportions in sexually active groups. As a result, a number of WHO and UN global strategies have been initiated in an attempt to control the spread of STIs.

STIs are the main preventable cause of infertility, particularly in women. However, some STIs remain asymptomatic before leading to serious reproductive complications and congenital infections, therefore appropriate diagnosis and treatment is essential.

Molecular diagnostic assays allow the accurate assessment of STIs in patients that present with similar symptoms or asymptomatic persons from at risk groups allowing early and accurate intervention and treatment.

The range of QCMD EQA schemes within this area focus on pathogens known to be the most common cause of STIs. The general aim of this group of EQA schemes is to assess the ability of laboratories in the detection of the selected pathogen.

	Page Number		Page Number
<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i>	45	Sexually Transmitted Infections I	62
Herpes simplex virus 1 & 2	27	Sexually Transmitted Infections II	63
Herpes simplex virus Drug Resistance	27	Syphilis	53
Human Papillomavirus (PreservCyt)	32	<i>Trichomonas vaginalis</i>	56
Human Papillomavirus (SurePath)	33		

### TRANSPLANT ASSOCIATED DISEASES

Advances in transplant medicine, including the development of immunosuppressive agents, has greatly improved the prospects of transplant recipients. However, pathogen infection and in particular viral reactivation remain significant contributors to transplant patient morbidity and mortality.

A number of viruses are of particular concern, these include: human herpes virus<sub>6</sub> (HHV<sub>6</sub>), human cytomegalovirus (CMV) and Epstein-Barr virus (EBV) along with human adenovirus (ADV), JC virus (JCV) and BK virus (BKV). Other opportunistic infections such as the parasite *Toxoplasma gondii* are also relevant. Advances in molecular diagnostics have allowed accurate pathogen assessment prior to transplant and accurate quantitative monitoring, particularly of viral activity over time, after the transplant has been performed. This in turn allows early and accurate pre-emptive intervention and antiviral drug therapy.

The range of QCMD EQA schemes within this area focus on those pathogens known to play a significant clinical role in transplant medicine. The general aim of this group of EQA schemes is to assess the ability of laboratories in the detection of the selected pathogen and where appropriate quantitative estimation is also evaluated.

	Page Number		Page Number
Adenovirus	15	Human cytomegalovirus	30
BK virus	16	JC virus	35
CMV Drug Resistance	17	Torque teno virus	40
Cytomegalovirus Whole Blood	18	<i>Toxoplasma gondii</i>	56
Epstein-Barr virus	20	Transplantation (viral)	65
Epstein-Barr virus Whole Blood	21		

## EQA GROUPS

### TYPING

Advances in the treatment and management of patient infection have seen important developments in recent years. In particular the introduction of novel antiviral drug therapies has improved the medium and long- term prospects of infected patients. However, the development of drug resistant pathogens is an increasing complication and remains a significant factor in the treatment of these patient groups.

The use of genotyping and sequencing technologies has allowed accurate pathogen assessment and monitoring of patient samples over time. This allows early and accurate determination of pathogen status. Which in turn allows pre- emptive intervention and management of antiviral drug therapy.

The range of QCMD EQA schemes within this area focus on pathogens known to play a significant clinical role in the management of infection. The general aim of this group of EQA schemes is to assess the ability of laboratories in the genetic determination of the selected pathogen and where appropriate the specific mutation points within the target gene.

	Page Number		Page Number
Bacterial 16S Ribosomal RNA	43	Herpes simplex virus Drug Resistance	27
CMV Drug Resistance	17	HIV-1 Drug Resistance	29
Enterovirus Typing	20	HIV-1 Drug Resistance (Integrase)	29
HBV Drug Resistance	21	Influenza Typing	34
HBV Genotyping	22	MALDI-TOF	59
HCV Drug Resistance	23	Methicillin Resistant <i>Staphylococcus aureus</i> Typing (epidemiology and outbreak studies)	49
HCV Genotyping	24	<i>Staphylococcus aureus</i> spa	52

---

### OTHER

QCMD are continuously expanding our range of EQA schemes, some of which are outside the defined EQA groups listed above.

	Page Number		Page Number
Dermatophytosis	55	Joint Infection	70
Group B Streptococcus	48	Viral Metagenomics NGS	72



# VIRAL EQA

## ADENOVIRUS

ADVDNA24 - QAV054133

To assess the proficiency of laboratories in the detection and quantitation of adenovirus.

To assess the proficiency of laboratories in the detection of different adenovirus serotypes including currently circulating serotypes of interest.

Feature	Available format(s)	
Catalogue Number	QAV054133_1	QAV054133_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Plasma
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Condition	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## B19 VIRUS

B19DNA24 - QAV034116

To assess the proficiency of laboratories in detection and quantitation of B19 virus.

Feature	Available format(s)	
Catalogue Number	QAV034116_1	QAV034116_2
Total Number of Challenges	1	2
Number of Panel Members	8	4
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## BK VIRUS

BKDNA24 - QAV144166

To assess the proficiency of laboratories molecular assays in detecting various types and concentrations of BK virus (BKV). To assess the proficiency of laboratories in the reliable quantitation of BKV viral load.

Feature	Available format(s)	
Catalogue Number	QAV144166_1	QAV144166_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Plasma and/or Urine
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CHIKUNGUNYA VIRUS

CHIKV24 - QAV154175

To assess the laboratory's ability to detect chikungunya virus using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)
Catalogue Number	QAV154175_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## CMV DRUG RESISTANCE

CMVDR24- QAV144169

To assess the laboratories' ability to detect CMV drug resistance mutations in kinase UL97 and polymerase UL54 genes using sequencing techniques.

Feature	Available format(s)
Catalogue Number	QAV144169_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma and/or Physiological Buffer
Panel Member Target Range	various mutations - kinase (UL97) and polymerase (UL54) genes
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Condition	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CORONAVIRUS

CVRNA24 - QAV064137

To assess the proficiency of laboratories in the detection of coronavirus. To assess the proficiency of laboratories in the detection of different coronavirus genotypes.

Feature	Available format(s)
Catalogue Number	QAV064137_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CYTOMEGALOVIRUS DRIED BLOOD SPOTS

CMVDBS24 - QAV064127

To assess the performance of laboratories in the detection of clinically relevant levels of human cytomegalovirus (CMV) from dried blood spots.

Feature	Available format(s)
Catalogue Number	QAV064127_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Dried Blood Spots
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	2x50µl
Panel Sample Pre-treatment Requirement	DNA extraction from dried blood spot
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## CYTOMEGALOVIRUS WHOLE BLOOD

CMVWB24 - QAV124150

To evaluate the ability of laboratories in the detection of CMV from whole blood samples. To assess the precision of molecular assays at clinically relevant viral loads.

Feature	Available format(s)	
Catalogue Number	QAV124150_1	QAV124150_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-30°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## DENGUE VIRUS

DENVRNA24 - QAV114148

To assess the proficiency of laboratories in the detection of dengue virus. To assess the proficiency of laboratories in distinguishing dengue virus from other flaviviruses.

Feature	Available format(s)
Catalogue Number	QAV114148_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## ENTEROVIRUS

EVRNA24 - QAV984104

To assess the ability of laboratories molecular assays to detect different types and concentrations of enterovirus (EV). To review the performance of laboratories quantitative EV molecular assays.

Feature	Available format(s)	
Catalogue Number	QAV984104_1	QAV984104_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## ENTEROVIRUS TYPING

EVTP24 - QAV164185

To assess laboratories ability to correctly identify specific enterovirus types using their routine molecular method and procedures.

Feature	Available format(s)
Catalogue Number	QAV164185_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## EPSTEIN-BARR VIRUS

EBVDNA24 - QAV024121

To assess the proficiency of laboratories in the detection and quantitation of Epstein-Barr virus (EBV).

Feature	Available format(s)	
Catalogue Number	QAV024121_1	QAV024121_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## EPSTEIN-BARR VIRUS WHOLE BLOOD

EBVWB24 - QAV134161

To assess the proficiency of laboratories in the detection and quantitation of Epstein-Barr virus (EBV) in whole blood samples.

Feature	Available format(s)	
Catalogue Number	QAV134161_1	QAV134161_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-30°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HBV DRUG RESISTANCE

HBVDR24 - QAV124160

To assess the performance of laboratories in the detection of drug resistance mutations in the hepatitis B virus (HBV) DNA polymerase gene using sequencing techniques and/or LiPA technology.

Feature	Available format(s)
Catalogue Number	QAV124160_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Various mutations – DNA polymerase
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**HBV GENOTYPING**

HBVGT24 - QAV064118

To assess the proficiency of laboratories in the correct genotyping of hepatitis B virus (HBV) using molecular methods.

Feature	Available format(s)
Catalogue Number	QAV064118_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Clinical material
Genotypic Variant	Various HBV genotypes
Matrix Panel Format	Plasma
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



## HCV DRUG RESISTANCE

HCVDR24 - QAV134167

The QCMD HCV Drug Resistance (HCVDR) scheme has to-date been based around resistance to the first generation Direct Acting Antiviral (DAA) NS3 protease inhibitors, boceprevir and telaprevir, which became widely available circa 2011. However the “previr” family of drugs are only effective against HCV genotype 1 infections limiting the scope of the HCVDR scheme to single genotype, single gene target. First generation DAAs were supplemented in 2014 with the release of the first “buvir” NS5b inhibitors for use against genotype 1 followed by the release of the first NS5a inhibitor “asvir” family of drugs in 2015, which are effective against both genotype 1 and 3 infections.

All three drug families are now in routine use and are included in both the WHO list of essential medicines and the national guidelines of several countries for treatment of HCV. Based on this the HCVDR scheme has been updated to reflect the current clinical environment with regards to drug resistance testing.

The aim of the HCVDR EQA is to assess the performance of laboratories in the detection of drug resistance mutations in the hepatitis C virus (HCV) genotypes 1 and 3 (NS3 and NS5 regions) using sequencing techniques.

Feature	Available format(s)
Catalogue Number	QAV134167_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Various mutations – NS3 and NS5a regions
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HCV GENOTYPING

HCVGT24 - QAV034117

To assess the proficiency of laboratories in the correct genotyping of hepatitis C virus (HCV) using molecular methods.

Feature	Available format(s)
Catalogue Number	QAV034117_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Clinical material
Genotypic Variant	Various HCV genotypes and subtypes
Matrix Panel Format	Plasma
Panel Member Target Range	Covering clinical range
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HEPATITIS A VIRUS

HAVRNA24 - QAV124156

To evaluate the ability of laboratories in the molecular detection of hepatitis A virus (HAV) in terms of sensitivity and specificity.

Feature	Available format(s)
Catalogue Number	QAV124156_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HEPATITIS B VIRUS

HBVDNA24 - QAV994110

To assess the proficiency of laboratories in the detection and quantitation of hepatitis B virus (HBV). To assess the proficiency of laboratories is the detection and quantitation of different HBV genotypes.

Feature	Available format(s)		
Catalogue Number	QAV994110_1	QAV994110_2	QAV994110_4
Total Number of Challenges	1	2	4
Number of Panel Members	8	4	4
Distribution / Testing Period	Q3	Q1 & Q3	Q1, Q2, Q3 & Q4

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HEPATITIS C VIRUS

HCVRNA24 - QAV994112

To assess the proficiency of laboratories in the detection and quantitation of hepatitis B virus (HBV). To assess the proficiency of laboratories is the detection and quantitation of different HBV genotypes.

Feature	Available format(s)		
Catalogue Number	QAV994112_1	QAV994112_2	QAV994112_4
Total Number of Challenges	1	2	4
Number of Panel Members	8	4	4
Distribution / Testing Period	Q3	Q1 & Q3	Q1, Q2, Q3 & Q4

Specifications	
Sample NA Target Source	Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HEPATITIS D VIRUS

HDV24 - QAV144170

To evaluate laboratories in the detection of HDV within the routine clinical setting.

Feature	Available format(s)
Catalogue Number	QAV144170_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Analysis type	Qualitative & Quantitative
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HEPATITIS E VIRUS

HEVRNA24 - QAV124157

To evaluate the ability of laboratories in the detection and quantification of hepatitis E virus (HEV).

Feature	Available format(s)
Catalogue Number	QAV124157_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	0.6 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately, Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HERPES SIMPLEX VIRUS 1 & 2

HSVDNA24 - QAV994105

To assess the ability of laboratories molecular assays to detect different types and concentrations of herpes simplex virus (HSV).To review the performance of laboratories quantitative HSV molecular assays.

Feature	Available format(s)	
Catalogue Number	QAV994105_1	QAV994105_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Transport medium and/or synthetic CSF
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HERPES SIMPLEX VIRUS DRUG RESISTANCE

HSVDR24 - QAV164184

To assess the performance of laboratories in the detection of drug resistance mutations in the herpes simplex virus thymidine kinase (UL23) and DNA polymerase (UL30) genes using sequencing techniques.

Feature	Available format(s)
Catalogue Number	QAV164184_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Various mutations - Thymidine Kinase (UL23) and DNA polymerase (UL30)
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

### HIV-1 (DNA)

HIVDNA24 - QAV034114

To assess the proficiency of laboratories in the detection of human immunodeficiency virus type 1 (HIV-1) pro-viral DNA.

Feature	Available format(s)	
Catalogue Number	QAV034114_1	QAV034114_2
Total Number of Challenges	1	2
Number of Panel Members	8	4
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured proviral cells
Matrix Panel Format	Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.2 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

### HIV-1 (RNA)

HIVRNA24 - QAV994108

To assess the proficiency of laboratories in detection and quantitation of human immunodeficiency virus (HIV) RNA. To assess the proficiency of laboratories in detection and quantitation of different HIV genotypes.

Feature	Available format(s)		
Catalogue Number	QAV994108_1	QAV994108_2	QAV994108_4
Total Number of Challenges	1	2	4
Number of Panel Members	8	4	4
Distribution / Testing Period	Q3	Q1 & Q3	Q1, Q2, Q3 & Q4

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HIV-1 DRUG RESISTANCE

HIVDR24 - QAV024131

To assess the performance of laboratories in the detection of drug resistance mutations in the HIV-1 protease and reverse transcriptase genes.

Feature	Available format(s)
Catalogue Number	QAV024131_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Various mutations - reverse transcriptase (RT) and protease (PR) genes
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HIV-1 DRUG RESISTANCE (INTEGRASE)

HIVDRint24 - QAV114146

To assess the performance of laboratories in the detection of drug resistance mutations in the HIV-1 integrase gene using sequencing techniques.

Feature	Available format(s)
Catalogue Number	QAV114146_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Panel Member Target Range	Various mutations - integrase (INT) gene
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Sequence Analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HIV-2

HIV2\_24 - QAV204212

To assess the proficiency of laboratories in the detection and quantitation of human immunodeficiency virus type2 (HIV-2).

Feature	Available format(s)	
Catalogue Number	QAV204212_1	QAV204212_2
Total Number of Challenges	1	2
Number of Panel Members	8	4
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.2ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HUMAN CYTOMEGALOVIRUS

CMVDNA24 - QAV014120

To assess the proficiency of laboratories in the detection and quantitation of human cytomegalovirus (CMV)

Feature	Available format(s)	
Catalogue Number	QAV014120_1	QAV014120_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



## HUMAN HERPES VIRUS 6

HHV6DNA24 - QAV084119

To assess the proficiency of laboratories' molecular assays in the detection of various types of human herpes virus 6 (HHV6). To assess the proficiency of laboratories in the reliable quantitation of HHV6 viral load.

Feature	Available format(s)	
Catalogue Number	QAV084119_1	QAV084119_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Genotypic Variant	Subtypes A and B
Matrix Panel Format	Transport Medium and/or Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HUMAN METAPNEUMOVIRUS

MPV24 - QAV054135

To assess the sensitivity and specificity of laboratories in the detection of human metapneumovirus (MPV). To assess the ability of laboratories in the detection of different human MPV types.

Feature	Available format(s)
Catalogue Number	QAV054135_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**HUMAN PAPILLOMAVIRUS (PRESERVCYT)**

HPVPRES24 - QAV094130

Human Papillomavirus (HPV) infection has been detected in over 95% of cervical cancers. The second most common cancer detected in females worldwide. The detection of HPV infection is an important part of the triage, with cytomorphological examination in the early detection of cervical cancer in scrapings. For effective triage, quantitative detection and accurate HPV-typing at clinically relevant levels is essential. The introduction of nucleic acid amplification technologies (NAT) and nucleic acid hybridisation assays has led to the development of sensitive, type specific diagnostic tests that can rapidly identify HPV infection. As a result, these tests are now of great practical and clinical relevance. The aim of the EQA is to assess the proficiency of laboratories in the detection of different high risk Human Papillomavirus types within a PreservCyt matrix.

Feature	Available format(s)	
Catalogue Number	QAV094130_1	QAV094130_2
Total Number of Challenges	1	2
Number of Panel Members	12	6
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Clinical material and/or cell lines containing HPV
Matrix Panel Format	Transport Medium (PreservCyt)
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	15-30°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## HUMAN PAPILLOMAVIRUS (SUREPATH)

HPVSURE24 - QAV184204

Human Papillomavirus (HPV) infection has been detected in over 95% of cervical cancers, the second most common cancer detected in females worldwide. The detection of HPV infections is an important part of the triage with cytomorphological examination in the early detection of cervical cancer in scrapings. For effective triage, quantitative detection and accurate HPV- typing at clinically relevant levels is essential. The introduction of nucleic acid amplification technologies (NAT) and nucleic acid hybridisation assays has led to the development of sensitive, type specific diagnostic tests that can rapidly identify HPV infection. As a result, these tests are now of great practical and clinical relevance.

To assess the proficiency of laboratories in the detection of different high risk Human Papillomavirus types within a SurePath™ matrix.

Feature	Available format(s)
Catalogue Number	QAV184204_1
Total Number of Challenges	1
Number of Panel Members	12
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Clinical material and/or cell lines containing HPV
Matrix Panel Format	Transport Medium (SurePath)
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## INFLUENZA A & B VIRUS

INFRNA24 - QAV054134

To assess the proficiency of laboratories in detection of influenza virus RNA.  
To assess the proficiency of laboratories in distinguishing influenza virus A and B.

Feature	Available format(s)	
Catalogue Number	QAV054134_1	QAV054134_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## INFLUENZA TYPING

INFTP24 - QAV064138

To assess the proficiency of laboratories in the detection of different influenza virus types, subtypes and lineages To assess the proficiency of laboratories in the typing and subtyping/lineage determination of influenza viruses.

Feature	Available format(s)
Catalogue Number	QAV064138_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## JC VIRUS

JCDNA24 - QAV074106

To assess the proficiency of laboratories molecular assays in detecting various types and concentrations of JC virus (JCV). To assess the proficiency of laboratories in the reliable quantitation of JCV viral load.

Feature	Available format(s)	
Catalogue Number	QAV074106_1	QAV074106_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Plasma
Units of Measurement	The primary unit is IU/ml however other units will be accepted
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## MEASLES / MUMPS

MM24 - QAV144171

To assess the proficiency of laboratories in the detection of mumps and/or measles using routine molecular methods.

Feature	Available format(s)
Catalogue Number	QAV144171_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## MERS CORONAVIRUS

MERS24 - QAV154181

To assess the proficiency of laboratories molecular technologies for the detection and determination of MERS-CoV from other coronaviruses.

Feature	Available format(s)
Catalogue Number	QAV154181_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## NOROVIRUS

NVRNA24 - QAV084139

To assess the specificity and sensitivity of laboratories in the detection of norovirus. To assess the ability of the laboratories to detect different norovirus genogroups.

Feature	Available format(s)	
Catalogue Number	QAV084139_1	QAV084139_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Physiological Buffer and/or Synthetic Faecal Matrix
Panel Member Sample Volume	1.0 ml VTM, 0.1 ml Buffer
Panel Sample Pre-treatment Requirement	NA samples are ready for analysis. Pre-treatment may be needed for SFM. Follow manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## PARAINFLUENZA VIRUS

PINFRNA24 - QAV064136

To assess the proficiency of laboratories in the detection of parainfluenza virus.

To assess the proficiency of laboratories in the detection of different parainfluenza virus types.

Feature	Available format(s)
Catalogue Number	QAV064136_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## PARECHOVIRUS

PEVRNA24 - QAV114145

To assess the ability of laboratories molecular assays to detect different types and concentrations of parechovirus.

Feature	Available format(s)	
Catalogue Number	QAV114145_1	QAV114145_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## RESPIRATORY SYNCYTIAL VIRUS

RSV24 - QAV054142

To assess the specificity and sensitivity of laboratories in the detection of respiratory syncytial virus (RSV) by NAT. To assess the ability of laboratories in the detection of different RSV types by NAT.

Feature	Available format(s)	
Catalogue Number	QAV054142_1	QAV054142_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## RHINOVIRUS

RVRNA24 - QAV064143

To assess the proficiency of laboratories in the detection of rhinovirus.

To assess the proficiency of laboratories in the detection of different rhinovirus genotypes

Feature	Available format(s)
Catalogue Number	QAV064143_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



## SARS-COV-2

SCV2\_24 - QAV204215

To assess the proficiency of laboratories in the detection of the new variant SARS-CoV-2 coronavirus including variants of concern (VOC). To assess the proficiency of laboratories in the differentiation of different coronavirus genotypes.

Feature	Available format(s)			
Catalogue Number	QAV204215_1A	QAV204215_1B	QAV204215_1C	QAV204215_1D
Total Number of Challenges	1	1	1	1
Number of Panel Members	5	5	5	5
Distribution / Testing Period	Q1	Q2	Q3	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## SARS-COV-2 ANTIGEN TESTING

SCV2Ag24 – QAS214224

To assess the proficiency of laboratories in the detection of the new variant SARS-CoV-2 coronavirus antigen including variant of concern (VOC).

The EQA is aimed at both laboratory based immunoassays as well as those used within the Point of Care (PoC) setting such as rapid lateral flow antigen tests and PoC analysers.

Feature	Available format(s)			
Catalogue Number	QAS214224_1A	QAS214224_1B	QAS214224_1C	QAS214224_1D
Total Number of Challenges	1	1	1	1
Number of Panel Members	5	5	5	5
Distribution / Testing Period	Q1	Q2	Q3	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various antigen testing methodologies
Storage / Shipment Conditions	Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## TORQUE TENO VIRUS

TTV24 - QAV184203

The aim of the Torque Teno Virus (TTV) EQA is to assess laboratories ability to detect TTV using routine molecular diagnostic platform and procedures.

Feature	Available format(s)
Catalogue Number	QAV184203_1
Total Number of Challenges	1
Number of Panel Members	6
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## VARICELLA-ZOSTER VIRUS

VZVDNA24 - QAV034103

To assess the ability of laboratories molecular assays to detect different concentrations of Varicella-Zoster virus (VZV). To review the performance of laboratories quantitative VZV molecular assays.

Feature	Available format(s)	
Catalogue Number	QAV034103_1	QAV034103_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Transport medium and/or synthetic CSF
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## WEST NILE VIRUS

WNVRNA24 - QAV104141

To assess the proficiency of laboratories in the detection of West Nile virus.

To determine the proficiency of laboratories in distinguishing West Nile virus from other flaviviruses.

Feature	Available format(s)
Catalogue Number	QAV104141_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## YELLOW FEVER VIRUS

YFV24 - QAV194207

To assess the proficiency of laboratories in the detection of yellow fever virus.

To determine the proficiency of laboratories in distinguishing yellow fever virus from other flaviviruses.

Feature	Available format(s)
Catalogue Number	QAV194207_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

**ZIKA VIRUS**

ZIKA24 - QAV164186

To assess the proficiency of laboratories in the detection of Zika virus and determine the proficiency of laboratories in distinguishing Zika virus from other flaviviruses.

Feature	Available format(s)
Catalogue Number	QAV164186_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## ATYPICAL MYCOBACTERIUM

NTM24 - QAB194208

To assess the proficiency of laboratories to detect atypical mycobacterium or non-tuberculous mycobacteria (NTM)

Feature	Available format(s)
Catalogue Number	QAB194208_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Pre-treatment not generally required - follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## BACTERIAL 16S RIBOSOMAL RNA

B16SrRNA24 - QAB164183

To assess the proficiency of laboratories to detect, identify and interpret which bacterial species are provided within each panel member using their routine 16S rRNA molecular diagnostic procedures.

Feature	Available format(s)
Catalogue Number	QAB164183_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Physiological Buffer
Panel Member Target Range	Covering Clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## BORDETELLA PERTUSSIS

BPDNA24 - QAB094132

To assess the proficiency of laboratories in the detection of Bordetella pertussis.

Feature	Available format(s)
Catalogue Number	QAB094132_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## BORRELIA BURGDORFERI SPP. (LYME DISEASE)

BbDNA24 - QAB114147

To assess the qualitative detection of B. burgdorferi sensu lato genospecies complex at different concentrations.

Feature	Available format(s)
Catalogue Number	QAB114147_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CHLAMYDIA PSITTACI

CPS24 - QAB134165

To assess the laboratories ability in the molecular detection of Chlamydia psittaci.

Feature	Available format(s)
Catalogue Number	QAB134165_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE

CTNG24 - QAB174191

To assess proficiency of laboratories in the detection of Chlamydia trachomatis and Neisseria gonorrhoeae using molecular technologies.

Feature	Available format(s)	
Catalogue Number	QAB174191_1	QAB174191_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured bacteria and/or Clinical material
Matrix Panel Format	Urine and/or Physiological Buffer and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CHLAMYDOPHILA PNEUMONIAE

CP24 - QAB084107

To assess the proficiency of laboratories in the correct detection of Chlamydomphila pneumoniae.

Feature	Available format(s)
Catalogue Number	QAB084107_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Bronchoalveolar Lavage (BAL) and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CLOSTRIDIUM DIFFICILE

CDDNA24 - QAB084125

A terminology update in the Clostridium field has introduced a name change from Clostridium difficile to Clostridioides difficile this has been adopted by the European Study Group for Clostridium difficile. Please note that QCMD will however continue to refer to this scheme and associated pathogens as Clostridium difficile at this time.

To assess the proficiency of laboratories in the molecular detection of Clostridium difficile.

Feature	Available format(s)	
Catalogue Number	QAB084125_1	QAB084125_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Synthetic Faecal Matrix
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for SFM. Follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



# BACTERIAL EQA

## DIARRHEAGENIC ESCHERICHIA COLI

E.COLI24 - QAB154179

To assess laboratories ability to detect diarrheagenic E. coli strains using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)
Catalogue Number	QAB154179_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Synthetic Faecal Matrix and/or Physiological Buffer and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for SFM. Follow test manufacturers IFU
Panel Analysis type	Molecular Typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## EXTENDED SPECTRUM $\beta$ -LACTAMASE AND CARBAPENEMASE

ESBL24 - QAB134162

To assess the laboratories ability to detect  $\beta$ -lactamase and carbapenemase coding genes in a clinical setting using their routine molecular diagnostic procedures.

Feature	Available format(s)
Catalogue Number	QAB134162_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Genotypic Variant	Various drug resistance strains
Matrix Panel Format	Physiological Buffer
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## GROUP B STREPTOCOCCUS

GBS24 - QAB174200

To assess the laboratories ability in the qualitative detection of group B Streptococcus using their routine molecular diagnostic procedures.

Feature	Available format(s)
Catalogue Number	QAB174200_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q4

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Plasma and/or Synthetic CSF and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## HELICOBACTER PYLORI

H.PYLORI24 - QAB164190

To assess the laboratories ability in the qualitative detection of H. pylori and where appropriate, the identification of H. pylori antibiotic resistance status using their routine molecular diagnostic procedures.

Feature	Available format(s)
Catalogue Number	QAB164190_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Synthetic Faecal Matrix and/or Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for the SFM. Follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## LEGIONELLA SPP.

LPDNA24 - QAB044122

To assess proficiency of laboratories in the detection of Legionella species.

Feature	Available format(s)
Catalogue Number	QAB044122_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q1

Specifications	
Sample NA Target Source	Cultured bacteria and/or Clinical material
Matrix Panel Format	Bronchoalveolar lavage (BAL) and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU.
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS TYPING (EPIDEMIOLOGY AND OUTBREAK STUDIES)

MRSATP24 - QAB074128

To assess the proficiency of laboratories in the molecular typing for outbreak analysis of Methicillin Resistant Staphylococcus aureus.

Feature	Available format(s)
Catalogue Number	QAB074128_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Target Range	Genetic variants of Staphylococcus aureus
Panel Member Sample Volume	0.2 ml
Panel Sample Pre-treatment Requirement	Culture followed by standard NA extraction
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS

MRSADNA24 - QAB064124

To assess the performance of laboratories in the detection of Methicillin Resistant Staphylococcus aureus.

Feature	Available format(s)
Catalogue Number	QAB064124_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## MYCOBACTERIUM TUBERCULOSIS

MTBDNA24 - QAB014129

To assess the proficiency of laboratories in the molecular detection of Mycobacterium tuberculosis complex.

Feature	Available format(s)	
Catalogue Number	QAB014129_1	QAB014129_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Sputum and/or Synthetic Sputum and/or Synthetic CSF
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Pre-treatment may be required for the sputum samples – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## MYCOBACTERIUM TUBERCULOSIS DRUG RESISTANCE

MTBDR24 - QAB194209

To assess the proficiency of laboratories to detect and differentiate MTB drug resistance strains using their routine molecular diagnostic procedures.

Feature	Available format(s)
Catalogue Number	QAB194209_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Genotypic Variant	Various drug resistance strains
Matrix Panel Format	Sputum and/or Synthetic Sputum and/or Synthetic CSF
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Pre-treatment may be required for the sputum samples – follow test manufacturers IFU
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## MYCOPLASMA GENITALIUM

MG24 - QAB184205

To assess the performance of laboratories in the detection of Mycoplasma genitalium.

Feature	Available format(s)
Catalogue Number	QAB184205_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Transport medium and/or Urine and/or Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## MYCOPLASMA PNEUMONIAE

MP24 - QAB174192

To assess the proficiency of laboratories in the correct detection of Mycoplasma pneumoniae.

Feature	Available format(s)
Catalogue Number	QAB174192_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Bronchoalveolar Lavage (BAL) and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## STAPHYLOCOCCUS AUREUS SPA

SASPA24 - QAB134164

To assess the laboratories ability in the use of spa typing as a technique for the identification of Staphylococcus aureus.

Feature	Available format(s)
Catalogue Number	QAB134164_1
Total Number of Challenges	1
Number of Panel Members	6
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Sample Volume	0.2 ml
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Liquid Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

# BACTERIAL EQA

## SYPHILIS

SYPH24 - QAB154180

To assess laboratories ability to detect *Treponema pallidum* using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)
Catalogue Number	QAB154180_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Urine and/or Physiological Buffer and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## VANCOMYCIN RESISTANT ENTEROCOCCI

VRE24 - QAB134163

This EQA will focus on the laboratories ability to detect and determine different VRE in clinically relevant sample types using molecular techniques.

Feature	Available format(s)
Catalogue Number	QAB134163_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Genotypic Variant	Various drug resistance strains
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Molecular typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# FUNGAL EQA

## ASPERGILLUS SPP.

ASPDNA24 - QAF104140

To assess the qualitative detection of Aspergillus species at different concentrations.

Feature	Available format(s)
Catalogue Number	QAF104140_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma and/or Physiological Buffer and/or Panel Member Sample Volume
Panel Member Target Range	Covering Clinical Range
Panel Member Sample Volume	1.0 ml
Panel Analysis type	Qualitative, Quantative for information purposes only
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for Panel Member Sample Volume. Follow test manufacturers IFU
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## CANDIDA SPP.

CANDNA24 - QAF124151

To evaluate the ability of laboratories to use molecular techniques for detection of Candida species.

Feature	Available format(s)
Catalogue Number	QAF124151_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma and/or Physiological Buffer
Panel Member Target Range	Covering clinical and analytical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



## DERMATOPHYTOSIS

DERMA24 - QAF164187

To assess laboratories ability to detect dermatophytes using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)
Catalogue Number	QAF164187_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## PNEUMOCYSTIS JIROVECII PNEUMONIA (PCP)

PCPDNA24 - QAF114144

To assess laboratories ability in the molecular detection of Pneumocystis jirovecii.

To assess the sensitivity of molecular assays in routine clinical use for the detection of P. jirovecii

Feature	Available format(s)
Catalogue Number	QAF114144_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Clinical material
Matrix Panel Format	Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis Type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# PARASITIC EQA

## TRICHOMONAS VAGINALIS

TV24 - QAP184202

To assess the performance of laboratories in the detection of Trichomonas vaginalis.

Feature	Available format(s)
Catalogue Number	QAP184202_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport medium, Urine and/or Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## TOXOPLASMA GONDII

TGDNA24 - QAP044123

To assess the qualitative detection of toxoplasma gondii at different concentrations.

Feature	Available format(s)	
Catalogue Number	QAP044123_1	QAP044123_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Amniotic Fluid and/or Plasma
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

# MPP EQA

## ARTHROPOD-BORNE VIRUSES

ARBO24 - QAM194206

The Arthropod-borne virus EQA will focus on the molecular detection and determination of different arthropod-borne viruses (including viruses from Flavi-, Toga-, Bunya-, and/or Reoviridae families). The panel is designed to represent various clinical scenarios (fever, haemorrhagic symptoms and/or neurological illness) and may include medically important arboviruses such as tick-borne encephalitis viruses, sandfly fever viruses, Japanese encephalitis viruses, Rift Valley fever viruses, Usutu virus, Murray Valley encephalitis virus, or St. Louis encephalitis virus. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)
Catalogue Number	QAM94206_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-Treatment Requirement	Reconstitution of lyophilised material
Panel Analysis Type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient
Accreditation/Regulatory Status	Accredited to ISO17043

## BACTERIAL GASTROENTERITIS

GASTROB24 - QAB124153

Different species of pathogenic bacteria are known to cause gastroenteritis. The panel members of this EQA will resemble clinical samples and may include current clinically relevant strains of Salmonella, Shigella, Yersinia, E.coli 0157, C. difficile or Campylobacter species. The aim of the Bacterial Gastroenteritis EQA is to assess laboratories ability to detect a range of bacterial pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)	
Catalogue Number	QAB124153_1	QAB124153_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Synthetic Faecal Matrix and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for SFM. Follow test manufacturers IFU
Panel Analysis type	Qualitative.
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**CENTRAL NERVOUS SYSTEM I (VIRAL MENINGITIS AND ENCEPHALITIS)**

CNSI24 - QAV174195

The central nervous system I (viral meningitis and encephalitis) EQA scheme will focus on the molecular detection and determination of various enterovirus, parechovirus, herpes simplex virus 1/2, Varicella-Zoster virus and JC virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAV174195_1	QAV174195_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Synthetic CSF and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**CENTRAL NERVOUS SYSTEM II (NON-VIRAL MENINGITIS AND ENCEPHALITIS)**

CNSII24 - QAM174196

The central nervous system II (non-viral meningitis and encephalitis) EQA scheme will focus on the molecular detection and determination of various *Listeria* spp, *Neisseria meningitidis*, *Streptococcus pneumoniae*, *Streptococcus agalactiae*, *Escherichia coli* K1, *Cryptococcus* spp., *Aspergillus* spp. or *Haemophilus influenzae* strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAM174196_1	QAM174196_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Synthetic CSF and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## MALDI-TOF

MALDI24 - QAB124155

The primary aim of this EQA is to evaluate the ability of laboratories in the detection and determination of different clinically relevant isolates using MALDI-TOF and other similar mass spectrometry based technologies in the routine microbiology laboratory.

Feature	Available format(s)
Catalogue Number	QAB124155_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Microbiological Medium and/or Transport Medium
Panel Member Target Range	Clinically relevant range of microorganisms for detection & determination
Panel Member Sample Volume	0.5 ml
Panel Sample Pre-treatment Requirement	Culture followed by standard MALDI protocol
Panel Analysis type	Typing
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## PARASITIC GASTROENTERITIS

GASTROP24 - QAP124154

Parasites are a frequent cause of gastroenteritis and are a growing risk in this age of global travel. The panel members of this EQA will resemble clinical samples and may include current clinically relevant strains of Giardia, Cryptosporidium, Dientamoeba, Blastocystis and Entamoeba. The aim of the Parasitic Gastroenteritis EQA is to assess laboratories' ability to detect a range of parasitic pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures.

Feature	Available format(s)	
Catalogue Number	QAP124154_1	QAP124154_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Synthetic Faecal Matrix and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0 ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for SFM. Follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## RESPIRATORY I

RESPI24 - QAV164188

The Respiratory I EQA will focus on the molecular detection and determination of various influenza A & B and respiratory syncytial virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAB164188_1	QAV164188_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical Range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis Type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## RESPIRATORY I PLUS

RESPIplus24 - QAM204216

The Respiratory I Plus EQA will focus on the molecular detection and determination of various influenza A & B, respiratory syncytial virus strains and SARS-Cov-2. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAM204216_1A	QAM204216_1B
Total Number of Challenges	1	1
Number of Panel Members	10	10
Distribution / Testing Period	Q2	Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering Clinical Range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis Type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**RESPIRATORY II**

RESPII24 - QAV164189

The Respiratory II EQA will focus on the molecular detection and determination of human metapneumovirus, respiratory adenoviruses, rhinoviruses, coronaviruses, enterovirus and parainfluenza viruses. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAV164189_1	QAV164189_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**RESPIRATORY III**

RESPIII24 - QAM174193

The Respiratory III EQA will focus on the molecular detection and determination of various Bordetella pertussis, Legionella pneumophila, Mycoplasma pneumoniae, Streptococcus pneumoniae or Haemophilus influenzae strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAM174193_1	QAM174193_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q3	Q1 & Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**SEPSIS**

SEPSIS24 - QAB164178

This EQA scheme consists of a range of pathogens associated with sepsis such as Staphylococcus, Serratia, Escherichia coli, Enterococcus, Streptococcus, Klebsiella, coagulase- negative Staphylococcus, Pseudomonas and Candida spp. The participating laboratory will be required to use their current molecular diagnostic processes and procedures for the detection and identification of microorganisms within blood or plasma based matrices.

Feature	Available format(s)
Catalogue Number	QAB164178_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood and/or Plasma and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**SEXUALLY TRANSMITTED INFECTIONS I**

STI\_I24 - QAB154177

The aim of the Sexually Transmitted Infection (STI) EQA is to assess the laboratories' ability to detect a range of sexual transmitted infections known to cause disease using their routine molecular diagnostic platform and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of Mycoplasma genitalium, Mycoplasma hominis, Trichomonas vaginalis, Ureaplasma urealyticum and Gardnerella vaginalis.

Feature	Available format(s)	
Catalogue Number	QAB154177_1	QAB154177_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Urine and/or Physiological Buffer and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043



## SEXUALLY TRANSMITTED INFECTIONS II

STI\_II24 - QAM174201

The sexually transmitted infection II EQA will focus on the molecular detection and determination of various Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum, and herpes simplex virus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

Feature	Available format(s)	
Catalogue Number	QAM174201_1	QAM174201_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Urine and/or Physiological Buffer and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	4.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

## TRANSPLANTATION (VIRAL)

TRANS24 - QAM174198

The viral transplant EQA scheme will focus on the molecular detection and determination of various cytomegalovirus, Epstein-Barr virus, human herpes virus 6, BK virus, B19 virus and adenovirus strains. The panel is designed to represent various clinical scenarios. Participating laboratories will be expected to test each panel using their appropriate molecular methods and to report their individual test results to QCMD.

Feature	Available format(s)
Catalogue Number	QAM174198_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q2

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Plasma and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative & Quantitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

**VIRAL GASTROENTERITIS**

## GASTROV24 - QAV124152

Viruses are a major cause of gastroenteritis outbreaks. It has been estimated that at least 50% of foodborne gastroenteritis cases are caused by noroviruses. Approximately another 20% of cases, and the majority of severe cases in children, are due to rotavirus. Other clinically significant viral enteropathogens include adenovirus, particularly types 40 and 41, and astroviruses. The aim of the Viral Gastroenteritis EQA is to assess laboratories ability to detect a range of viral pathogens known to cause gastroenteritis using their routine molecular diagnostic platform and procedures. The panel members will resemble clinical samples and may include current clinically relevant strains of norovirus, rotavirus, astrovirus, sapovirus and adenovirus.

Feature	Available format(s)	
Catalogue Number	QAV124152_1	QAV124152_2
Total Number of Challenges	1	2
Number of Panel Members	10	5
Distribution / Testing Period	Q4	Q2 & Q4

Specifications	
Sample NA Target Source	Cultured material and/or Clinical material
Matrix Panel Format	Synthetic Faecal Matrix and/or Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment may be required for SFM. Follow test manufacturers IFU
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice
Accreditation/Regulatory Status	Accredited to ISO17043

# EQA PILOT STUDIES

## BABESIA

BABESIA24 - QAP214219

Pathogens of the genus *Babesia* (Family: Babesiidae, Order: Piroplasmida) are important blood parasites in mammals and less frequently in birds. Of the more than 100 known tick-borne species, only a few have been identified as causing human infections. Of zoonotic importance are parasites of bovine babesiosis (*Babesia divergens* and *B. divergens*-like forms), rodent babesiosis (*B. microti*) and a few other *Babesia* species like *B. venatorum* in wild deer. During a blood meal, hard-bodied ticks (e.g. *Ixodes ricinus*) inoculate sporozoites with their saliva, which, like plasmodia, enter human erythrocytes and undergo asexual reproduction.

In Europe, *B. divergens* is the main pathogen of human babesiosis. Occasionally, there also occur infections with *B. microti* and *B. venatorum* (EU1). Single infections have been reported in various European countries, however, the total number of around 50 documented clinically severe cases from mostly splenectomised patients in Europe is very low. But infections are probably asymptomatic, as indicated by serologic surveys. In the United States, *B. microti* is the agent most frequently identified in more than 300 known clinical manifestations (in the Northeast and Midwest), and can occur in non-splenectomised individuals. *Babesia duncani* has been isolated in patients in Washington and California. MO-1 has been isolated from patients in Missouri. Other cases have been reported from Africa, Mexico, Japan, Taiwan and India (*B. microti* or unidentified *Babesia*).

The diagnosis of an acute infection is confirmed through identification of *Babesia* on microscopic examination of Wright or Giemsa-stained thin blood-film or detection of *Babesia* nucleic acid, whereby nucleic acid testing (NAT) offers a better correlate of active infection. Also, nucleic acid detection-based tests, such as polymerase chain reaction (PCR) and transcription-mediated amplification (TMA), more effectively identify low-level infections than other laboratory tests, making them important for donor screening and donation testing to reduce the risk of transfusion-transmitted babesiosis.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection and identification of *Babesia* species causing human babesiosis.

Feature	Available format(s)
Catalogue Number	QAP214219_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient

## CHAGAS

CHAGAS24 - QAP214217

Trypanosoma cruzi is the causative agent of Chagas disease or American trypanosomiasis. T. cruzi is primarily transmitted by triatomine bugs, known as "kissing bugs"; other transmission routes such as transplacental, blood transfusion, organ transplantation and contaminated food are known.

Since parasite detection is difficult during both the acute and the latent phase of infection, antibody detection plays a crucial role in laboratory diagnostics. Serologic testing is also the method for blood donor screening. Compared to conventional blood smears techniques, molecular tools such as PCR offer improved sensitivity for detection of acute and early congenital disease and are considered the test of choice in these settings. Also, PCR is maybe useful for monitoring reactivation in immunosuppressed patients or parasitological response to treatment.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of Trypanosoma cruzi causing Chagas disease.

Feature	Available format(s)
Catalogue Number	QAP214217_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient

**FRANCISELLA TULARENSIS**

FRATUL24 - QAB214220

Tularemia is a severe zoonosis that can affect humans as well as animals. Reservoirs are lagomorphs or rodents, such as wild rabbits and field mice, and blood-sucking arthropods, like ticks and mosquitoes. The pathogen occurs in the northern hemisphere (in Europe, the number of human cases is approximately 800 annually, with Sweden and Finland reporting the highest notification rates). Hunters, people employed in the agriculture and forestry industries, and lab staff are at the highest risk for infection. The pathogens are transmitted through the skin or mucous membrane of infected animals. Transmission occurs when contaminated meat (rabbit) that hasn't been properly heated is eaten, when contaminated water is drunk, by breathing in contaminated dust and through arthropod bites (e.g. ticks).

As the disease is relatively rare and the symptoms non-specific, tularemia can easily be misdiagnosed. Laboratory confirmation of tularemia consists in detecting the bacteria in a biological sample or a specific antibody response. Cultivation of the bacterium is rarely used for the diagnosis as the bacteria are slow growing and require a BSL-3 laboratory. Molecular methods (i.e. PCR) are rapid and can allow identification of the subspecies. Serological methods are routinely used for diagnosis and are considered highly specific despite cross-reactions with Brucella, Yersinia, Proteus, Legionella and Mycoplasma species may occur.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection of Francisella tularensis.

Feature	Available format(s)
Catalogue Number	QAB214220_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium and/or Physiological Buffer
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient

## GROUP A STREPTOCOCCUS

GAS24 - QAB234226

Group A Streptococcus (GAS) is one of the most common causes of bacterial infections of the throat and skin. GAS or Streptococcus pyogenes is also the cause of 'Scarlet fever' which most commonly affects children between 5 and 15 years old. Early antibiotic treatment has been shown to be effective in reducing both the transmission and severity of disease therefore rapid diagnosis is key. The SARS-CoV-2 pandemic resulted in an influx of near patient / PoC molecular testing platforms, with GAS added to the test menu of several commercial instruments for use within a non-laboratory, point of impact test setting or in a 'statim' or 'out of hours' capacity within the central laboratory. We have therefore introduced a pilot EQA to assess the performance of molecular GAS testing, allowing test sites to assess the performance of their assays.

Feature	Available format(s)
Catalogue Number	QAB234226_1_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice

## HBV DRIED BLOOD SPOTS

HBVDBS24 - QAV214223

To assess the performance of laboratories in the detection of clinically relevant levels of hepatitis B virus (HBV) from dried blood spots.

Feature	Available format(s)
Catalogue Number	QAV214223_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Dried Blood Spots
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	2x50µl
Panel Sample Pre-treatment Requirement	DNA extraction from dried blood spot
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	Ambient

**HCV DRIED BLOOD SPOTS**

HCVDBS24 - QAV214222

To assess the performance of laboratories in the detection of clinically relevant levels of hepatitis C virus (HCV) from dried blood spots.

Feature	Available format(s)
Catalogue Number	QAV214222_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Dried Blood Spots
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	2x50µl
Panel Sample Pre-treatment Requirement	DNA extraction from dried blood spot
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	Ambient

**HIV DRIED BLOOD SPOTS**

HIVDBS24 - QAV214221

To assess the performance of laboratories in the detection of clinically relevant levels of human immunodeficiency virus (HIV) from dried blood spots.

Feature	Available format(s)
Catalogue Number	QAV214221_1
Total Number of Challenges	1
Number of Panel Members	8
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured virus and/or Clinical material
Matrix Panel Format	Dried Blood Spots
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	2x50µl
Panel Sample Pre-treatment Requirement	DNA extraction from dried blood spot
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	Ambient

## EQA PILOT STUDIES

### JOINT INFECTION

JOINT24 - QAM244227

Bone and Joint infection diagnosis can be challenging as the symptoms are similar to other common conditions such as gout and rheumatoid arthritis. Culturing can require up to two weeks due to the potentially fastidious nature of the pathogens associated with this type of infection. Average sensitivity rates of approximately 72% have been recorded and this can be further reduced where antibiotics have been administered.

The aim of the joint infection pilot study is to assess the ability of laboratories to detect a range of Gram positive, Gram negative and fungal pathogens alongside common resistance markers using their routine molecular diagnostic platforms and procedures. The panel members will resemble clinical samples and will include current clinically relevant strains.

Feature	Available format(s)
Catalogue Number	QAM244227_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-treatment Requirement	Thaw and test immediately. Pre-treatment not generally required – follow test manufacturers IFU
Panel Analysis type	Qualitative.
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice



## MALARIA

### MALARIA24 - QAP214218

Malaria is considered the most important parasitic disease in humans. The pathogens of malaria are protozoans of the genus *Plasmodium* (Order: Haemospororida). The blood parasites are transmitted by female *Anopheles* mosquitoes.

Of the five human pathogenic *Plasmodium* species [*Plasmodium falciparum* (causative agent of Malaria tropica), *Plasmodium ovale* and *Plasmodium vivax* (causative agents of *M. tertiana*), *Plasmodium malariae* (causative agent of *M. quartana*) and in Southeast Asia *Plasmodium knowlesi*], *P. falciparum* causes the majority of malaria and almost all fatal cases.

Malaria occurs primarily in tropical and less frequently in subtropical areas. While *P. falciparum* dominates throughout Africa (90% in Africa, 45% in Asia and Oceania, 5% in Latin America), *P. vivax* is the second most prevalent malaria species in most of the Latin American and Asian malaria areas. The range of *P. ovale* is mainly restricted to West African regions with few foci outside the continent (except Latin America). *P. malariae* is found worldwide, but at a lower incidence compared to the other species. *P. knowlesi* is identified since 2004 as the causative agent of a focal, especially in Malaysia occurring malaria form. Due to the large number of imported cases in Europe, malaria (in particular caused by *P. falciparum*) is mainly a travel medicine issue.

In patients with fever of unknown cause and stay in a malaria area, acute malaria must be excluded, even if the stay was several years ago. The acute diagnosis is based on the detection of the pathogen in thin and thick blood films and / or the detection of *Plasmodium*-specific antigens or its DNA. Serological examinations are not suitable for acute diagnosis. Although microscopy is still the most routinely used method for malaria diagnosis by clinical laboratories, nucleic acid tests (NAT) have become increasingly popular, particularly in reference laboratories and specialised institutes.

The pilot EQA scheme will assess the proficiency of laboratories in the correct detection and identification of *Plasmodium* species causing human malaria.

Feature	Available format(s)
Catalogue Number	QAP214218_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Whole Blood
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	Lyophilised
Panel Sample Pre-treatment Requirement	Reconstitution of lyophilised material
Panel Analysis type	Qualitative. Quantitative for information purposes only
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	2-8°C / Lyophilised Ambient

## POXVIRUSES

POX24 - QAV224225

Due to the global outbreak of monkeypox and increasing demand for laboratory preparedness, we have introduced a pilot EQA scheme for poxviruses that will include inactivated monkeypox virus and other orthopoxviruses (Cowpox, and Vaccinia). This will offer laboratories, that have recently set up generic orthopoxvirus or specific monkeypox virus molecular diagnostics, the opportunity to assess the performance of their assays.

Feature	Available format(s)
Catalogue Number	QAV224225_1
Total Number of Challenges	1
Number of Panel Members	10
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured and/or Clinical material
Matrix Panel Format	Transport Medium
Panel Member Target Range	Covering clinical range
Panel Member Sample Volume	1.0ml
Panel Sample Pre-Treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis Type	Qualitative
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice

## VIRAL METAGENOMICS NGS

NGSMETA\_24 - QAV204213

Viral metagenomics has been proposed as an unbiased method with unique clinical opportunities to identify the composition of clinical specimens without introduction of selection bias due to processing methods. The techniques used in these protocols are however complex and analysis methods require standardisation. This EQA pilot study aims to assess performance of existing metagenomics protocols as currently implemented by participating laboratories. Samples will be provided which will mimic cerebrospinal fluid samples containing known viral pathogens including enterovirus, herpes simplex virus and influenza virus.

Performance will be assessed based on the qualitative identification of viruses present in the samples, at the family, genus, species and subtype levels.

Feature	Available format(s)
Catalogue Number	QAV204213_1
Total Number of Challenges	1
Number of Panel Members	5
Distribution / Testing Period	Q3

Specifications	
Sample NA Target Source	Cultured material
Matrix Panel Format	Synthetic CSF + human cell lines
Panel Member Sample Volume	1.0ml
Panel Sample Pre-Treatment Requirement	Ready for analysis. Treat as clinical samples and analyse accordingly
Panel Analysis Type	Sequence analysis
Panel Testing	Evaluated by various molecular methodologies
Storage / Shipment Conditions	<-20°C / Frozen on Dry-ice

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Adenovirus</b>							<b>Page 15</b>
ADVDNA24	QAV054133_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV054133_2	2	5	Q2, Q4			
<b>Arthropod-borne viruses</b>							<b>Page 57</b>
ARBO24	QAM194206_1	1	10	Q3	Ambient	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Aspergillus spp.</b>							<b>Page 54</b>
ASPDNA24	QAF104140_1	1	8	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Atypical mycobacterium</b>							<b>Page 43</b>
NTM24	QAB194208_1	1	10	Q1	Ambient	Qualitative	Bacterial EQA
<b>B19 virus</b>							<b>Page 15</b>
B19DNA24	QAV034116_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
		QAV034116_2	2	4			
<b>Babesia</b>							<b>Page 65</b>
BABESIA24	QAP214219_1	1	10	Q3	Ambient	Qualitative	Pilot Study
<b>Bacterial 16S Ribosomal RNA</b>							<b>Page 43</b>
B16SrRNA24	QAB164183_1	1	8	Q3	Dry-ice	Typing	Bacterial EQA
<b>Bacterial Gastroenteritis</b>							<b>Page 57</b>
GastroB24	QAB124153_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
		QAB124153_2	2	5			
<b>BK virus (BKV)</b>							<b>Page 16</b>
BKDNA24	QAV144166_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
		QAV144166_2	2	5			
<b>Bordetella pertussis</b>							<b>Page 44</b>
BPDNA24	QAB094132_1	1	10	Q2	Dry-ice	Qualitative	Bacterial EQA
<b>Borrelia burgdorferi spp. (Lyme Disease)</b>							<b>Page 44</b>
BbDNA24	QAB114147_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Candida spp.</b>							<b>Page 54</b>
CANDNA24	QAF124151_1	1	10	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Central Nervous System I (viral Meningitis and Encephalitis)</b>							<b>Page 58</b>
CNSI24	QAV174195_1	1	10	Q4 Q2, Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
		QAV174195_2	2				

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Central Nervous System II (Non-viral Meningitis and Encephalitis)</b>							<b>Page 58</b>
CNSII24	QAM174196_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAM174196_2	2	5	Q2, Q4			
<b>Chagas</b>							<b>Page 66</b>
CHAGAS24	QAP214217_1	1	10	Q3	Ambient	Qualitative	Pilot Study
<b>Chikungunya virus (CHIKV)</b>							<b>Page 16</b>
CHIKV24	QAV154175_1	1	10	Q3	Ambient	Qualitative	Viral EQA
<b>Chlamydia psittaci</b>							<b>Page 45</b>
CPS24	QAB134165_1	1	8	Q2	Dry-ice	Qualitative	Bacterial EQA
<b>Chlamydia trachomatis and Neisseria gonorrhoeae</b>							<b>Page 45</b>
CTNg24	QAB174191_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
		QAB174191_2	2	5			
<b>Chlamydophila pneumoniae</b>							<b>Page 46</b>
CP24	QAB084107_1	1	5	Q2	Dry-ice	Qualitative	Bacterial EQA
<b>Clostridium difficile (CD)</b>							<b>Page 46</b>
CDDNA24	QAB084125_1	1	10	Q4	Dry-ice	Qualitative	Bacterial EQA
		QAB084125_2	2	5			
<b>Coronavirus (CoV)</b>							<b>Page 17</b>
CVRNA24	QAV064137_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA
<b>Cytomegalovirus (CMV) Dried Blood Spots</b>							<b>Page 18</b>
CMVDBS24	QAV064127_1	1	8	Q3	Ambient	Qualitative	Viral EQA
<b>Cytomegalovirus (CMV) Drug Resistance</b>							<b>Page 17</b>
CMVDR24	QAV144169_1	1	5	Q2	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Cytomegalovirus (CMV)</b>							<b>Page 30</b>
CMVDNA24	QAV014120_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
		QAV014120_2	2	5			
<b>Cytomegalovirus (CMV) Whole Blood</b>							<b>Page 18</b>
CMVWB24	QAV124150_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
		QAV124150_2	2	5			
<b>Dengue virus (DENV)</b>							<b>Page 19</b>
DENVRNA24	QAV114148_1	1	10	Q3	Ambient	Qualitative	Viral EQA

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Dermatophytosis</b>							<b>Page 55</b>
DERMA24	QAF164187_1	1	8	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Diarheagenic Escherichia coli</b>							<b>Page 47</b>
E.COLI24	QAB154179_1	1	8	Q3	Dry-ice	Typing	Bacterial EQA
<b>Enterovirus (EV)</b>							<b>Page 19</b>
EVRNA24	QAV984104_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV984104_2	2	5	Q1, Q3			
<b>Enterovirus Typing (EV)</b>							<b>Page 20</b>
EVTP24	QAV164185_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Epstein-Barr virus (EBV)</b>							<b>Page 20</b>
EBVDNA24	QAV024121_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV024121_2	2	5	Q2, Q4			
<b>Epstein-Barr virus (EBV) Whole Blood</b>							<b>Page 21</b>
EBVWB24	QAV134161_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV134161_2	2	5	Q2, Q4			
<b>Extended Spectrum <math>\beta</math>-lactamase and Carbapenemase</b>							<b>Page 47</b>
ESBL24	QAB134162_1	1	8	Q3	Dry-ice	Typing	Bacterial EQA
<b>Francisella tularensis</b>							<b>Page 68</b>
FRATUL24	QAB214220_1	1	10	Q3	Ambient	Qualitative	Pilot Study
<b>Group A Streptococcus</b>							<b>Page 68</b>
GAS24	QAB234226_1	1	10	Q3	Dry-ice	Qualitative	Pilot Study
<b>Group B Streptococcus</b>							<b>Page 48</b>
GBS24	QAB174200_1	1	8	Q4	Dry-ice	Qualitative	Bacterial EQA
<b>Helicobacter pylori</b>							<b>Page 48</b>
H.PYLORI24	QAB164190_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Hepatitis A virus (HAV)</b>							<b>Page 24</b>
HAVRNA24	QAV124156_1	1	8	Q1	Dry-ice	Qualitative	Viral EQA
<b>Hepatitis B virus (HBV)</b>							<b>Page 25</b>
HBVDNA24	QAV994110_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994110_2	2	4	Q1, Q3			
	QAV994110_4	4	4	Q1, Q2, Q3, Q4			

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Hepatitis B virus (HBV) – Dried Blood Spots</b>							<b>Page 69</b>
HBVDBS24	QAV214223_1	1	8	Q3	Ambient	Qualitative	Pilot Study
<b>Hepatitis B virus (HBV) Drug Resistance</b>							<b>Page 21</b>
HBVDR24	QAV124160_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Hepatitis B virus (HBV) Genotyping</b>							<b>Page 22</b>
HBVGT24	QAV064118_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Hepatitis C virus (HCV)</b>							<b>Page 25</b>
HCVRNA24	QAV994112_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994112_2	2	4	Q1, Q3			
	QAV994112_4	4	4	Q1, Q2, Q3, Q4			
<b>Hepatitis C virus (HCV) – Dried Blood Spots</b>							<b>Page 69</b>
HCVDBS24	QAV214222_1	1	8	Q3	Ambient	Qualitative	Pilot Study
<b>Hepatitis C virus (HCV) Drug Resistance</b>							<b>Page 23</b>
HCVDR24	QAV134167_1	1	5	Q3	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Hepatitis C virus (HCV) Genotyping</b>							<b>Page 24</b>
HCVGT24	QAV034117_1	1	8	Q1	Dry-ice	Typing	Viral EQA
<b>Hepatitis D virus (HDV)</b>							<b>Page 26</b>
HDV24	QAV144170_1	1	8	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Hepatitis E virus (HEV)</b>							<b>Page 26</b>
HEVRNA24	QAV124157_1	1	8	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
<b>Herpes simplex virus 1 &amp; 2 (HSV)</b>							<b>Page 27</b>
HSVDNA24	QAV994105_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV994105_2	2	5	Q1, Q3			
<b>Herpes simplex virus Drug Resistance</b>							<b>Page 27</b>
HSVDR24	QAV164184_1	1	5	Q1	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Human herpes virus 6 (HHV6)</b>							<b>Page 31</b>
HHV6DNA24	QAV084119_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV084119_2	2	5	Q2, Q4			

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Human Immunodeficiency virus type 1 (HIV-1) – DNA</b>							<b>Page 28</b>
HIVDNA24	QAV034114_1	1	8	Q3	Dry-ice	Qualitative	Viral EQA
	QAV034114_2	2	4	Q1, Q3			
<b>Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance</b>							<b>Page 29</b>
HIVDR24	QAV024131_1	1	5	Q4	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Human Immunodeficiency virus type 1 (HIV-1) – Drug Resistance (Integrase)</b>							<b>Page 29</b>
HIVDRint24	QAV114146_1	1	5	Q4	Dry-ice	Drug Resistance / Sequencing	Viral EQA
<b>Human Immunodeficiency virus type 1 (HIV-1) – Dried Blood Spots</b>							<b>Page 70</b>
HIVDBS24	QAV214221_1	1	8	Q3	Ambient	Qualitative	Pilot Study
<b>Human Immunodeficiency virus type 1 (HIV-1) – RNA</b>							<b>Page 28</b>
HIVRNA24	QAV994108_1	1	8	Q3	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV994108_2	2	4	Q1, Q3			
	QAV994108_4	4	4	Q1, Q2, Q3, Q4			
<b>HIV-2</b>							<b>Page 30</b>
HIV2_24	QAV204212_1	1	8	Q3	Dry-ice	Qualitative	Viral EQA
	QAV204212_2	2	4	Q1, Q3			
<b>Human metapneumovirus (MPV)</b>							<b>Page 31</b>
MPV24	QAV054135_1	1	8	Q2	Dry-ice	Qualitative	Viral EQA
<b>Human Papillomavirus (HPV) – PreservCyt</b>							<b>Page 32</b>
HPVPRES24	QAV094130_1	1	12	Q3	Ambient / Specialist	Qualitative	Viral EQA
	QAV094130_2	2	6	Q1, Q3			
<b>Human Papillomavirus (Surepath)</b>							<b>Page 33</b>
HPVSURE24	QAV184204_1	1	12	Q3	Ambient	Qualitative	Viral EQA
<b>Influenza A &amp; B virus (FLU)</b>							<b>Page 34</b>
INFRNA24	QAV054134_1	1	10	Q4	Dry-ice	Qualitative	Viral EQA
	QAV054134_2	2	5	Q2, Q4			
<b>Influenza Typing</b>							<b>Page 34</b>
INFTP24	QAV064138_1	1	8	Q4	Dry-ice	Typing	Viral EQA
<b>JC virus (JCV)</b>							<b>Page 35</b>
JCDNA24	QAV074106_1	1	10	Q4	Dry-ice	Qualitative & Quantitative	Viral EQA
	QAV074106_2	2	5	Q2, Q4			

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Joint Infection</b>							<b>Page 70</b>
JOINT24	QAM244227_1	1	10	Q3	Dry-ice	Qualitative	Pilot Study
<b>Legionella spp.</b>							<b>Page 49</b>
LPDNA24	QAB044122_1	1	10	Q1	Dry-ice	Qualitative	Bacterial EQA
<b>Malaria</b>							<b>Page 71</b>
MALARIA24	QAP214218_1	1	10	Q3	Ambient	Qualitative	Pilot Study
<b>MALDI-TOF</b>							<b>Page 59</b>
MALDI24	QAB124155_1	1	10	Q3	Dry-ice	Typing	Multi-Pathogen / Syndromic EQA
<b>Measles / Mumps</b>							<b>Page 35</b>
MM24	QAV144171_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
<b>MERS coronavirus (MERS-CoV)</b>							<b>Page 36</b>
MERS24	QAV154181_1	1	8	Q2	Dry-ice	Qualitative	Viral EQA
<b>Methicillin Resistant Staphylococcus aureus (MRSA)</b>							<b>Page 50</b>
MRSADNA24	QAB064124_1	1	10	Q3	Ambient	Qualitative	Bacterial EQA
<b>Methicillin Resistant Staphylococcus aureus (MRSA) – Typing</b>							<b>Page 49</b>
MRSATP24	QAB074128_1	1	8	Q3	Ambient	Typing	Bacterial EQA
<b>Mycobacterium tuberculosis (MTB)</b>							<b>Page 50</b>
MTBDNA24	QAB014129_1 QAB014129_2	1 2	10 5	Q3 Q1, Q3	Ambient	Qualitative	Bacterial EQA
<b>Mycobacterium tuberculosis Drug Resistance</b>							<b>Page 51</b>
MTBDR24	QAB194209_1	1	8	Q3	Ambient	Typing	Bacterial EQA
<b>Mycoplasma genitalium</b>							<b>Page 51</b>
MG24	QAB184205_1	1	10	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Mycoplasma pneumoniae</b>							<b>Page 52</b>
MP24	QAB174192_1	1	5	Q2	Dry-ice	Qualitative	Bacterial EQA



## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Norovirus (NV)</b>							<b>Page 36</b>
NVRNA24	QAV084139_1	1	10	Q4	Dry-ice	Qualitative	Viral EQA
	QAV084139_2	2	5	Q2, Q4			
<b>Parainfluenza virus (PIV)</b>							<b>Page 37</b>
PINFRNA24	QAV064136_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA
<b>Parasitic Gastroenteritis</b>							<b>Page 59</b>
GastroP24	QAP124154_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAP124154_2	2	5	Q2, Q4			
<b>Parechovirus (HPeV)</b>							<b>Page 37</b>
PeVRNA24	QAV114145_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV114145_2	2	5	Q1, Q3			
<b>Pneumocystis jirovecii pneumonia (PCP)</b>							<b>Page 55</b>
PCPDNA24	QAF114144_1	1	10	Q3	Dry-ice	Qualitative	Fungal EQA
<b>Poxviruses</b>							<b>Page 72</b>
POX24	QAV224225_1	1	10	Q3	Dry-ice	Qualitative	Pilot Study
<b>Respiratory I</b>							<b>Page 60</b>
RESPI24	QAV164188_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAV164188_2	2	5	Q1, Q3			
<b>Respiratory I Plus</b>							<b>Page 60</b>
RESPIplus24	QAM204216_1A	1	10	Q2	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAM204216_1B	1	10	Q4			
<b>Respiratory II</b>							<b>Page 61</b>
RESPII24	QAV164189_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAV164189_2	2	5	Q1, Q3			
<b>Respiratory III</b>							<b>Page 61</b>
RESPIII24	QAM174193_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAM174193_2	2	5	Q1, Q3			
<b>Respiratory syncytial virus (RSV)</b>							<b>Page 38</b>
RSV24	QAV054142_1	1	10	Q4	Dry-ice	Qualitative	Viral EQA
	QAV054142_2	2	5	Q2, Q4			

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Rhinovirus (RV)</b>							<b>Page 38</b>
RVRNA24	QAV064143_1	1	10	Q2	Dry-ice	Qualitative	Viral EQA
<b>SARS-CoV-2</b>							<b>Page 39</b>
SCV2_24	QAV204215_1A	1	5	Q1	Dry-ice	Qualitative	Viral EQA
	QAV204215_1B	1	5	Q2			
	QAV204215_1C	1	5	Q3			
	QAV204215_1D	1	5	Q4			
<b>SARS-CoV-2 Antigen Testing</b>							<b>Page 39</b>
SCV2Ag24	QAS214224_1A	1	5	Q1	Ambient	Qualitative	Viral EQA
	QAS214224_1B	1	5	Q2			
	QAS214224_1C	1	5	Q3			
	QAS214224_1D	1	5	Q4			
<b>Sepsis</b>							<b>Page 62</b>
SEPSIS24	QAB164178_1	1	10	Q3	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
<b>Sexually Transmitted Infections I</b>							<b>Page 62</b>
STI_I24	QAB154177_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAB154177_2	2	5	Q2, Q4			
<b>Sexually Transmitted Infections II</b>							<b>Page 63</b>
STI_II24	QAM174201_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAM174201_2	2	5	Q2, Q4			
<b>Staphylococcus aureus spa</b>							<b>Page 52</b>
SASPA24	QAB134164_1	1	6	Q3	Ambient	Typing	Bacterial EQA
<b>Syphilis</b>							<b>Page 53</b>
SYPH24	QAB154180_1	1	8	Q3	Dry-ice	Qualitative	Bacterial EQA
<b>Torque teno virus (TTV)</b>							<b>Page 40</b>
TTV24	QAV184203_1	1	6	Q4	Dry-ice	Qualitative	Viral EQA
<b>Toxoplasma gondii</b>							<b>Page 56</b>
TGDNA24	QAP044123_1	1	10	Q3	Ambient	Qualitative	Parasitic EQA
	QAP044123_2	2	5	Q1, Q3			
<b>Transplantation (viral)</b>							<b>Page 65</b>
TRANS24	QAM174198_1	1	10	Q2	Dry-ice	Qualitative & Quantitative	Multi-Pathogen / Syndromic EQA

## APPENDIX I: SUMMARY SPECIFICATIONS AND DISTRIBUTION SCHEDULE

TARGET PATHOGEN							PAGE NUMBER
SCHEME CODE	CATALOGUE NUMBER	NO. OF CHALLENGES	PANEL MEMBERS PER CHALLENGE	DISTRIBUTION DATE(S)/ TESTING PERIOD	SHIPPING CONDITIONS	ANALYSIS TYPE	SCHEME TYPE
<b>Trichomonas vaginalis</b>							<b>Page 56</b>
TV24	QAP184202_1	1	8	Q3	Dry-ice	Qualitative	Parasitic EQA
<b>Vancomycin Resistant Enterococci (VRE)</b>							<b>Page 53</b>
VRE24	QAB134163_1	1	10	Q3	Dry-ice	Typing	Bacterial EQA
<b>Varicella-Zoster virus (VZV)</b>							<b>Page 40</b>
VZVDNA24	QAV034103_1	1	10	Q3	Dry-ice	Qualitative	Viral EQA
	QAV034103_2	2	5	Q1, Q3			
<b>Viral Gastroenteritis</b>							<b>Page 64</b>
GastroV24	QAV124152_1	1	10	Q4	Dry-ice	Qualitative	Multi-Pathogen / Syndromic EQA
	QAV124152_2	2	5	Q2, Q4			
<b>Viral Metagenomics NGS</b>							<b>Page 72</b>
NGSmeta_24	QAV204213_1	1	5	Q3	Dry-ice	Sequencing	Pilot Study
<b>West Nile virus (WNV)</b>							<b>Page 41</b>
WNVRNA24	QAV104141_1	1	10	Q3	Ambient	Qualitative	Viral EQA
<b>Yellow Fever Virus</b>							<b>Page 41</b>
YFV24	QAV194207_1	1	8	Q3	Ambient	Qualitative	Viral EQA
<b>Zika Virus</b>							<b>Page 42</b>
ZIKA24	QAV164186_1	1	10	Q3	Ambient	Qualitative	Viral EQA

